National Pharmacare has been a topic of discussion in Canada for several decades. Yet despite numerous studies calling for a universal single-payer pharmacare program to ensure all Canadians have access to prescription drugs, the country’s drug system remains a patchwork of public and private plans.
This education session will provide a critical analysis on the Pharmacare Options and what plan sponsors should be aware of as we look to the horizon.
Warren Xu, Public Policy Analyst, will present GlaxoSmithKline’s research on their work over the past several months. The policy team at GlaxoSmithKline (GSK) has been working to understand, summarize, and visualize the various models of pharmacare that have been published in recent reports. The team has been building and testing their thinking with a variety of stakeholders, including federal and provincial policy makers, academics, and key thought leaders.
The increasing pressure in funding for private and public drug plans continues to escalate. Sarah Hedayat, Team Lead at Gallagher Benefits Consulting, will discuss the potential impact the National Pharmacare Plan may have on plan sponsor drug benefits, and what employers should consider in reviewing their benefits plans.
|